Market
Scenario:
Diabetes is a metabolic disorder in which the body
glucose level is elevated. Gestational diabetes is a temporary or permanent
form of diabetes in which the body does not produce adequate amounts of insulin
to regulate sugar during pregnancy. It may also be called glucose intolerance
or carbohydrate intolerance. According to the International Diabetes Federation
in 2016, it was estimated that 420 million adult
population is suffering from diabetes which is increasing at the rate of 8.4%
and is expected to reach 625 million by 2040. According to the American
Pregnancy Association, approximately 2-5% of pregnant women develop gestational
diabetes; this number may increase to 7-9% of mothers who are more likely to
have risk factors. Increasing prevalence of the gestational diabetic population
is the major driving factor for the growth of the market.
Moreover, increasing obese population,
increasing healthcare expenditure, and strong encouragement from the government
have also contributed to the growth of the market. According to research,
smoking increases the possibility of diabetes; more than 60% of the global
population smokes, this has increased the risk of diabetes and contributed to
the growth of the market. However, lack of awareness among people and cost
issues may lead to restrain the growth of the market.
The global gestational diabetic market
is expected to grow at a CAGR of 5.4% during forecast period.
Intended
Audience
Biotechnological
institutes
Pharmaceutical
companies
Government and Private
Laboratories
Research and
Development (R&D) Companies
Market Research and
Consulting Service Providers
Medical Research
Laboratories
Segmentation
The global gestational diabetes market is segmented
on the basis of types, administration, treatment, and end users.
On the basis of types, the market is segmented into
type A1, type A2 and others.
On the basis of administration, the market is
categorised into oral, intravenous, and other.
On the basis of treatment, the market is segmented
into monitoring, drug treatment, and non-pharmacological treatment. Monitoring
is further segmented into urinary glucose testing, oral glucose tolerance test,
and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2
inhibitors, alpha-glucosidase inhibitors, and others
On the basis of end users, the market is segmented
into hospital, retail pharmacy and other.
Regional Analysis
America dominates the global gestational diabetes
market owing to large patient population. Apart from this, increasing number of
obese people, changing lifestyle and increasing healthcare expenditure have
boosted the growth of the market in America. According to the Centers for
Disease Control and Prevention (2014), 73.5 million adults in the US were
diagnosed with high cholesterol level. Increasing cholesterol level and smoking
increases the possibility of causing diabetes. Additionally, increasing
awareness among the people regarding different monitoring procedures and
well-developed technology has also contributed to the growth of the market.
Europe is the second largest gestational diabetes
market, which is followed by Asia Pacific. Huge smoking population,
availability of funds for research, and government support for research &
development will drive the market.
Asia Pacific is the fastest growing region for the
market due to the presence of a huge patient population, continuously
developing economies, and increasing need for the better treatment.
On the other hand, the Middle East & Africa has
the least share in the global gestational diabetes market due to presence of
poor economy especially in Africa region. Majority of the market of this region
is hold by Middle East due to well-developed healthcare sector and huge
healthcare expenditure.
Key
players for global gestational diabetes market
Antares Pharma (US), INJEX Pharma AG (Germany), 3M
(US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo
Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland),
Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US),
Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South
Korea), and Takeda (Japan).
Detailed Table
of Contents:
Table Of Content
1. Report Prologue
2. Market Introduction
2.1
Definition
2.2
Scope Of The Study
2.2.1
Research Objective
2.2.2
Assumptions
2.2.3
Limitations
3. Research Methodology
3.1
Introduction
3.2
Primary Research
3.3
Secondary Research
3.4
Market Size Estimation
4. Market Dynamics
4.1
Drivers
4.2
Restrains
4.3
Opportunities
4.4
Challenges
4.5 Macroeconomic
Indicators
4.6
Technology Trends & Assessment
5. Market Factor Analysis
5.1
Porters Five Forces Analysis
5.1.1
Bargaining Power Of Suppliers
5.1.2
Bargaining Power Of Buyers
5.1.3
Threat Of New Entrants
5.1.4
Threat Of Substitutes
5.1.5
Intensity Of Rivalry
...Continued
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
